The organizers of Prix Galien Russia today announced the official list of nominees for the Prix Galien Russia 2014 awards. Prix Galien is considered to be the biomedical industry’s highest honor to recognize scientific innovation for biopharmaceutical and medical technology products that improve the human condition. This year’s ceremony will be held at the Pashkov […]
Despite the disproportionately high numbers of females in the healthcare and life-sciences industries, and the fact that women are the main decision makers when it comes to family health, there is still inequality in pay and career progression. Carla Smith gives us the stats and explains why equality in the health sector just makes sense. […]
2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city of Wuhan in China circulated around the world in just months, wreaking havoc on economies and disrupting the lives of effectively the entire global population […]
Adam Dunnett, secretary general of the European Union Chamber of Commerce in China (European Chamber) outlines the organization’s three key roles of advocacy, providing business intelligence and strengthening the European business community. He also details an extraordinarily productive past six months – during which the European Chamber held meetings with Premier Li Keqiang and Vice […]
On the 100th anniversary of the development of insulin, regular PharmaBoardroom contributor Brendan Shaw* examines the shocking global disparities in access to the lifesaving drug, but does not point the finger of blame at the pharmaceutical industry. Instead, Shaw highlights the high barriers of entry that dissuade these companies from entering certain markets and calls […]
Jan Hux, the president and CEO of Diabetes Canada calls for governments to place greater importance on partnerships with patient groups for the making of big decisions in healthcare. The establishment of a multi-stakeholder group, including patient organizations and patient representatives, could provide feedback and public policy recommendations to government on improving the affordability, […]
Although the COVID-19 pandemic and the subsequent rush to develop diagnostics, therapeutics, and vaccines dominated the global headlines in 2020, PharmaBoardroom’s network of industry insiders contributed pieces across a broad swathe of topics this year. See below for a selection of articles ranging from cross country pricing collaborations to AI ethics, cell and gene therapy […]
Adriana Stara, general manager Central Europe & Baltics at Allergan, explains how her previous experiences have prepared her to drive Allergan’s business in the region. Stara also delves into Allergan’s marketing strategy in medical aesthetics, the company’s strongest franchise locally, and the characteristics of the Czech market when it comes to consumer behaviour. As AbbVie’s […]
The organizers of Prix Galien Russia today announced the official list of nominees for the Prix Galien Russia 2014 awards. Prix Galien is considered to be the biomedical industry’s highest honor to recognize scientific innovation for biopharmaceutical and medical technology products that improve the human condition. This year’s ceremony will be held at the Pashkov […]
The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma multinationals explain what MEA means to their global groups and their key areas of focus today. Biogen: Awareness is Crucial Biogen’s manager for the […]
The Saudi medtech market was valued at USD 2.25 billion in 2017 and is expected to reach USD 3.87 billion at a CAGR of 9.5 percent by 2023, according to Market Research Future. Like other parts of the Saudi healthcare continuum, the country’s medtech industry is extremely dynamic and changing rapidly, as the five trends […]
Ahmed Elfangary, country manager of DHL Express Egypt, highlights the company’s leadership position in the Egyptian logistics field, while aiming to be a strong partner of the government. He also explains how DHL is a partner of choice in the healthcare and life sciences field and his ambition to make Egypt the MENA hub for […]
John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the past risk getting left behind. “Drug” companies have a unique opportunity to invent a different market for themselves. It begins by telling a new […]
2019 was a year of innovation and disruption in the life sciences industry. From artificial intelligence to cell and gene therapy, and from generics and biosimilars to geopolitics and healthcare reform, PharmaBoardroom is proud to have collaborated with industry thought leaders to publish their insights on the year’s top trends in pharma and healthcare. Here […]
John G. Singer outlines why a focus on patients’ adherence to their medication is not necessarily useful in working to improve health outcomes and why innovation is more sorely needed in markets and strategies, not technologies and analytics. “Monty Python and the Holy Grail,” which opened yesterday at the Cinema 2, is a marvelously […]
Adam Vojtěch, Minister of Health of the Czech Republic, gives an update on the Ministry’s achievements and directives exactly halfway through his term of office. Highlighting the full implementation of electronic prescription as a key milestone, Vojtěch shares the efforts being put into refreshing the healthcare system, a reform that starts with strengthening the role […]
Few Turkish companies are experiencing such a transformational moment as GEN. Just in 2021, the Ankara-based organization made its public debut at the Istanbul Stock Exchange and signed an exclusive collaboration agreement with a Dutch biotech company for the development and commercialization of a therapy against Alzheimer’s and other neurodegenerative diseases. GEN’s CEO, Abidin Gülmüş, […]
The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma multinationals explain what MEA means to their global groups and their key areas of focus today. Biogen: Awareness is Crucial Biogen’s manager for the […]
Adam Dunnett, secretary general of the European Union Chamber of Commerce in China (European Chamber) outlines the organization’s three key roles of advocacy, providing business intelligence and strengthening the European business community. He also details an extraordinarily productive past six months – during which the European Chamber held meetings with Premier Li Keqiang and Vice […]
CEO Abdelhakim Tahri introduces women’s health player Gynebio Pharma, how the company is disrupting the Moroccan pharmaceutical industry through its range of contraceptive and fertility products, and his vision for regional expansion. Our major focus when creating Gynebio Pharma was creating a company and a production facility that would benefit Morocco, but also Africa […]
Although the COVID-19 pandemic and the subsequent rush to develop diagnostics, therapeutics, and vaccines dominated the global headlines in 2020, PharmaBoardroom’s network of industry insiders contributed pieces across a broad swathe of topics this year. See below for a selection of articles ranging from cross country pricing collaborations to AI ethics, cell and gene therapy […]
The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their vital role leading operations in the world’s most innovative and lucrative pharma market, translating global cultures to a US reality, and the challenges of attracting and retaining talent. Ivan Cheung, […]
Geoffrey Guy, David Meek, Tae Han Kim, Pierre Moustial, Vivek Sharma, Antonio Portela and many other remarkable people that are shaping the global life sciences industry shared with PharmaBoardroom valuable insights on the companies they lead and their vision for the future. Geoffrey Guy Geoffrey Guy is the chairman and founder of GW Pharma, the UK’s […]
EY’s Abhay Bangi highlights the key trends across the ASEAN life sciences space, how the COVID-19 pandemic has accelerated them, and charts Singapore’s course towards becoming a world-class biotech investment destination. Value-Based healthcare in this part of the world will be implemented in different ways. It will come less through contracts, but more through […]
Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is relatively young, Gilead is one of the biggest pharmaceutical companies in Italy. Our footprint in the country is threefold, on one side, we have a traditional commercial presence conducting […]
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in the early studies of remdesivir as a treatment against severe COVID-19 disease; how Gilead is working to eliminate viral Hepatitis by 2030; and the potential […]
IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from procurement to regulatory, reimbursement, clinical trials, localisation, health economics, and digitalisation. Mostafa also outlines how IQVIA has adapted its Saudi offering to cater to this […]
Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is relatively young, Gilead is one of the biggest pharmaceutical companies in Italy. Our footprint in the country is threefold, on one side, we have a traditional commercial presence conducting […]
The executive president of Laboratorios Rubió, Carlos Rubió, analyses the fundamentals behind the Catalan company’s double-digit growth, its international expansion plan, which includes the United States, the doubling of capacity at their Castellbisbal plant, and the challenges of the Spanish market. A producer of hydroxychloroquine, Laboratorios Rubió experienced skyrocketing demand during the early phases of […]
Mecomed is the largest medical devices, imaging, and diagnostics trade association in the Middle East and Africa (MEA). Rami Rajab, chairman, highlights the role of the association in shaping the region’s regulatory environment and industry code of conduct, the giant transformation that digital health has brought about, and explains how Mecomed’s different working groups work […]
Interviews
Interviews
Interviews
Interviews
Interviews
Interviews
Interviews
David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities involving companies with artificial intelligence/machine learning platforms and technologies and their application to healthcare companies. Artificial Intelligence Advances in technologies, an incorporation of entrants from outside the industry and changing consumer expectations are driving a global […]
Chimeric antigen receptor (CAR)-T therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as a revolutionary, perhaps even decisive, new pillar in the war on cancer.
IBM Watson Health’s Director for Global Life Sciences & Go-To Market Leader for Europe & Asia Pacific Christina Busmalis gives her insights into how AI and greater utilisation of real-world evidence is shaping the global biopharmaceutical industry, including the tangible results she has seen so far, and the lengthy path still left to travel. […]
It has been a full three years since, first Novartis, then Gilead, took the medical world by storm by gaining FDA approvals for chimeric antigen receptor (CAR) T-cell therapies, billed as the cornerstone of future cancer care. While such treatments are undoubtedly game-changing from a scientific standpoint and have demonstratively delivered considerable clinical benefits to […]
It has been a full three years since, first Novartis, then Gilead, took the medical world by storm by gaining FDA approvals for chimeric antigen receptor (CAR) T-cell therapies, billed as the cornerstone of future cancer care. While such treatments are undoubtedly game-changing from a scientific standpoint and have demonstratively delivered considerable clinical benefits to a small number of patients with severe and uncommon forms of cancer, they have yet to come anywhere close to fulfilling investor expectations.
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are the producers of Sativex and Epiodiolex, the former being the world’s first prescription medicine derived from the cannabis plant — it has approval in multiple countries for the treatment of spasticity due to multiple sclerosis.
Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses.
“Timely correction” for booming biotech stocks in March
Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses. In the last five to ten years, for instance, we have witnessed innovative pharma investing deeply in high-risk frontier research involving […]
Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and gene therapy manufacturing and the areas in which biopharma firms need to invest in order to succeed in this emergent field. Cell and gene therapies (CGT) are the next evolution of personalized health care. These products are potentially […]
Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses. In the last five to ten years, for instance, we have witnessed innovative pharma investing deeply in high-risk frontier research involving stem cells and the harnessing of a patient’s own immune system to attack the onset of a disease.
Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses.
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare diseases. We are very excited to put Chiesi’s decades of experience in drug development and dedication to patients to work to make a positive difference in the treatment of many […]
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association and new breakthroughs in Coronavirus diagnostics. Government amends legislation around emergency response to diseases The State Duma, as is called the lower house of […]
See our Cookie Privacy Policy Here
